Looking ahead, future action lines should include deeper mechanistic studies of ADA1 activity and its effects on CAR T cell biology, development of advanced preclinical models that more accurately mimic the tumor microenvironment, and multi-modal clinical trials exploring combinations with other metabolic or immunotherapeutic interventions. The gene discussed is ADA; the disease is neoplasm.